Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Ying Lan, Nan Yang, Yirong Wang, Yan Yang, Min Xu & Qin He. (2023) Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 2093-2103.
Read now
Read now
Stephen A. Brunton & D. Kyle Hogarth. (2023) Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns. Postgraduate Medicine 0:0, pages 1-19.
Read now
Read now
Yanling Ding, Lina Sun, Ying Wang, Jing Zhang & Yahong Chen. (2022) Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1051-1067.
Read now
Read now
Mario Cazzola, Paola Rogliani, Luigino Calzetta, Josuel Ora & Maria Gabriella Matera. (2022) A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology 15:3, pages 269-283.
Read now
Read now
Leah B Sansbury, Chanchal Bains, David A Lipson, Afisi S Ismaila & Sarah H Landis. (2021) Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1255-1264.
Read now
Read now
Gerard Criner & Sean Duffy. (2021) Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol. Current Medical Research and Opinion 37:2, pages 275-284.
Read now
Read now
Andriana I Papaioannou, Stelios Loukides, Petros Bakakos, Epameinondas N Kosmas, Nikoletta Rovina, Paschalis Steiropoulos, Evangellia Fouka, Georgios Hillas, Georgios Patentalakis, Marousa Kouvela & Nikos Tzanakis. (2020) Dual Bronchodilator in the Era of Triple Therapy. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2695-2705.
Read now
Read now
Roland Buhl, Michael Dreher, Stephanie Korn, Christian Taube, Christian Stock, Christoph M Zehendner, Anke Kondla & Claus F Vogelmeier. (2020) A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2601-2608.
Read now
Read now
Neil S. Skolnik, Trang Susan Nguyen, Aarisha Shrestha, Riju Ray, Thomas C. Corbridge & Stephen A. Brunton. (2020) Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgraduate Medicine 132:2, pages 198-205.
Read now
Read now
Chad Moretz, Lucie Sharpsten, Lindsay GS Bengtson, Eleena Koep, Lisa Le, Junliang Tong, Richard H Stanford, Beth Hahn & Riju Ray. (2019) Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1721-1737.
Read now
Read now
Maria Gabriella Matera, Luigino Calzetta, Ermanno Puxeddu, Paola Rogliani & Mario Cazzola. (2018) A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety 17:5, pages 509-517.
Read now
Read now
Claus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, Nicolas Roche, Jørgen Vestbo, Chau Thach, Donald Banerji, Robert Fogel, Francesco Patalano, Petter Olsson, Konstantinos Kostikas & Jadwiga A Wedzicha. (2018) Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1125-1134.
Read now
Read now
Amnon Ariel, Alan Altraja, Andrey Belevskiy, Piotr W Boros, Edvardas Danila, Matjaz Fležar, Vladimir Koblizek, Zvi G Fridlender, Kosta Kostov, Alvils Krams, Branislava Milenkovic, Attila Somfay, Ruzena Tkacova, Neven Tudoric, Ruxandra Ulmeanu & Arschang Valipour. (2018) Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 45-56.
Read now
Read now
Syed Mohammad Tariq & Enson C Thomas. (2017) Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1877-1882.
Read now
Read now
Chunxue Bai, Masakazu Ichinose, Sang Haak Lee, Kwan Ho Lee, Olaf Jöns, Ulrich Bothner, Yihua Zhao & Roland Buhl. (2017) Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3329-3339.
Read now
Read now
Gustavo J Rodrigo, David Price, Antonio Anzueto, Dave Singh, Pablo Altman, Giovanni Bader, Francesco Patalano, Robert Fogel & Konstantinos Kostikas. (2017) LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 907-922.
Read now
Read now
Eric Derom, Guy G Brusselle & Guy F Joos. (2016) Efficacy of tiotropium–olodaterol fixed-dose combination in COPD. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 3163-3177.
Read now
Read now
Claus Vogelmeier, Nanshan Zhong, Michael J Humphries, Karen Mezzi, Robert Fogel, Giovanni Bader, Francesco Patalano & Donald Banerji. (2016) Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 3189-3197.
Read now
Read now
Masakazu Ichinose, Hiroyuki Taniguchi, Ayako Takizawa, Lars Grönke, Lazaro Loaiza, Florian Voß, Yihua Zhao & Yoshinosuke Fukuchi. (2016) The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2017-2027.
Read now
Read now
Tomohiro Tamura & Hiroaki Satoh. (2016) Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2909-2911.
Read now
Read now
Articles from other publishers (50)
Hong Chen, Zheng-Xu Deng, Jian Sun, Qiang Huang, Lan Huang, Yong-Hong He, Chunlan Ma & Ke Wang. (2023) Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD. Chest 163:1, pages 100-114.
Crossref
Crossref
Michelle N. Schroeder, Hailee M. Sens & Shaina K. Shah. (2022) De-Prescribing Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Narrative Review. Journal of Pharmacy Practice, pages 089719002211441.
Crossref
Crossref
Mònica Monteagudo, Alexa Nuñez, Miriam Barrecheguren & Marc Miravitlles. (2022) Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. Archivos de Bronconeumología 58:10, pages 699-707.
Crossref
Crossref
Martine Hoogendoorn, Isaac Corro Ramos, Stéphane Soulard, Jennifer Cook, Erkki Soini, Emma Paulsson & Maureen Rutten-van Mölken. (2021) Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open 11:8, pages e049675.
Crossref
Crossref
Hong Chen, Jian Sun, Qiang Huang, Yongqi Liu, Mengxin Yuan, Chunlan Ma & Hao Yan. (2021) Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Jennifer K. Quint, Jukka Montonen, Daina B. Esposito, Xintong He, Leslie Koerner, Laura Wallace, Alberto de la Hoz & Marc Miravitlles. (2021) Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Advances in Therapy 38:5, pages 2249-2270.
Crossref
Crossref
Hong Chen, Ke Wang, Tao Yuan, Xiaoming Wang, Lan Huanng, Zhenhuan Jiang, Keyang Chen & Yuejun Du. (2021) Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. International Immunopharmacology 93, pages 107447.
Crossref
Crossref
Tarek M. Mostafa, Gamal A. El-Azab, Ghada A. Atia & Noran S. Lotfy. (2021) The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study. Current Therapeutic Research 94, pages 100625.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2020) Tiotropium in chronic obstructive pulmonary disease – a review of clinical development. Respiratory Research 21:1.
Crossref
Crossref
Gary T. Ferguson, Nicola Brown, Chris Compton, Thomas C. Corbridge, Kelly Dorais, Charles Fogarty, Catherine Harvey, Morrys C. Kaisermann, David A. Lipson, Neil Martin, Frank Sciurba, Marjorie Stiegler, Chang-Qing Zhu & David Bernstein. (2020) Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respiratory Research 21:1.
Crossref
Crossref
David A. Lipson, Ruby Birk, Noushin Brealey & Chang-Qing Zhu. (2020) 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study. Advances in Therapy 37:12, pages 4894-4909.
Crossref
Crossref
S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina & V. O. Smirnova. (2020) Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 13:2, pages 101-111.
Crossref
Crossref
James D. Chalmers, Irena F. Laska, Frits M.E. Franssen, Wim Janssens, Ian Pavord, David Rigau, Melissa J. McDonnell, Nicolas Roche, Don D. Sin, Daiana Stolz, Samy Suissa, Jadwiga Wedzicha & Marc Miravitlles. (2020) Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal 55:6, pages 2000351.
Crossref
Crossref
Suzanne G Bollmeier & Aaron P Hartmann. (2020) Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. American Journal of Health-System Pharmacy 77:4, pages 259-268.
Crossref
Crossref
Jie He & Jiang-Tao Lin. (2020) A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease. Medicine 99:16, pages e19789.
Crossref
Crossref
Luigino Calzetta, Fabiano Di Marco, Francesco Blasi, Mario Cazzola, Stefano Centanni, Claudio Micheletto, Andrea Rossi & Paola Rogliani. (2019) Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology & Therapeutics 59, pages 101855.
Crossref
Crossref
N. Struß, J. Bauersachs, T. Welte & J. M. Hohlfeld. (2019) Left heart function in COPDLinksherzfunktion bei COPD. Herz 44:6, pages 477-482.
Crossref
Crossref
Hannah A. Blair. (2019) Tiotropium/Olodaterol: A Review in COPD. Drugs 79:9, pages 997-1008.
Crossref
Crossref
Mario Malerba, Valentina Foci, Filippo Patrucco, Patrizia Pochetti, Matteo Nardin, Corrado Pelaia & Alessandro Radaeli. (2019) Single Inhaler LABA/LAMA for COPD. Frontiers in Pharmacology 10.
Crossref
Crossref
François Maltais, Alan Hamilton, Florian Voß & M. Reza Maleki-Yazdi. (2019) Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD. Advances in Therapy 36:4, pages 962-968.
Crossref
Crossref
Anna E. WallaceShuchita KailaValentina BayerAsif ShaikhMayura U. ShindeVincent J. WilleyMark B. NapierJoseph R. Singer. (2019) Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. Journal of Managed Care & Specialty Pharmacy 25:2, pages 205-217.
Crossref
Crossref
Eric Derom, Guy G. Brusselle & Guy F. Joos. (2019) The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Therapeutic Advances in Respiratory Disease 13, pages 175346661984342.
Crossref
Crossref
Eneida M. Harrison & Victor Kim. (2019) Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. Respiratory Medicine: X 1, pages 100009.
Crossref
Crossref
Eric Derom & Clara M. Ionescu. 2019. Lung Function Testing in the 21st Century. Lung Function Testing in the 21st Century
171
184
.
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray & Richard H. Stanford. (2018) The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. Multidisciplinary Respiratory Medicine 13:1.
Crossref
Crossref
James D. Chalmers, Chris Poole, Samantha Webster, Abigail Tebboth, Scott Dickinson & Alicia Gayle. (2018) Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD). Respiratory Research 19:1.
Crossref
Crossref
Peter A. Frith, Samiha Ashmawi, Srikanth Krishnamurthy, Alev Gurgun, Sashka Hristoskova, Virginia Pilipovic, Anna Marie Hamann, Arthur Backer, Petter Olsson, Konstantinos Kostikas & Dina V. Diaz. (2018) Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: The FLASH randomized controlled trial. Respirology 23:12, pages 1152-1159.
Crossref
Crossref
Barbara P. Yawn & Barry Make. (2018) Treatment of Chronic Obstructive Pulmonary Disease in the Primary Care Setting: How Can We Achieve More for Our Patients?. The American Journal of Medicine 131:9, pages 7-14.
Crossref
Crossref
Chris Garvey & Gerard J. Criner. (2018) Impact of Comorbidities on the Treatment of Chronic Obstructive Pulmonary Disease. The American Journal of Medicine 131:9, pages 23-29.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2018) Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. Chest 154:2, pages 242-248.
Crossref
Crossref
Antonio Anzueto & Marc Miravitlles. (2018) The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. The American Journal of Medicine 131:6, pages 608-622.
Crossref
Crossref
Jens M Hohlfeld, Jens Vogel-Claussen, Heike Biller, Dominik Berliner, Korbinian Berschneider, Hanns-Christian Tillmann, Simone Hiltl, Johann Bauersachs & Tobias Welte. (2018) Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. The Lancet Respiratory Medicine 6:5, pages 368-378.
Crossref
Crossref
Steven D. Deas & Nikhil Huprikar. (2018) Dual bronchodilator therapy for chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine 24:2, pages 130-137.
Crossref
Crossref
Marc Miravitlles, Seungjae BaekVatsal VithlaniRahul Lad. (2018)
Optimal Bronchodilation for COPD Patients: Are All Long-Acting β
2
-Agonist/Long-Acting Muscarinic Antagonists the Same?
. Tuberculosis and Respiratory Diseases 81:3, pages 198.
Crossref
Crossref
Marc Miravitlles, Gerard Urrutia, Alexander G. Mathioudakis & Julio Ancochea. (2017) Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. Respiratory Research 18:1.
Crossref
Crossref
Marc Miravitlles, Antonio Anzueto & José R. Jardim. (2017) Optimizing bronchodilation in the prevention of COPD exacerbations. Respiratory Research 18:1.
Crossref
Crossref
Donald P. Tashkin & Christian Taube. (2017) Triple Therapy for Chronic Obstructive Pulmonary Disease Management. Are Our Expectations Fulfilled?. American Journal of Respiratory and Critical Care Medicine 196:4, pages 402-404.
Crossref
Crossref
Joachim H. Ficker, Klaus F. Rabe & Tobias Welte. (2017) Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology & Therapeutics 45, pages 19-33.
Crossref
Crossref
Kai M. Beeh, Pierre-Regis Burgel, Frits M. E. Franssen, Jose Luis Lopez-Campos, Stelios Loukides, John R. Hurst, Matjaž Fležar, Charlotte Suppli Ulrik, Fabiano Di Marco, Daiana Stolz, Arschang Valipour, Brian Casserly, Björn Ställberg, Konstantinos Kostikas & Jadwiga A. Wedzicha. (2017) How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine 196:2, pages 139-149.
Crossref
Crossref
Masakazu Ichinose, Yoshiaki Minakata, Takashi Motegi, Jun Ueki, Tetsuo Seki, Tatsuhiko Anzai, Ayako Takizawa, Lars Grönke & Kazuto Hirata. (2017) Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease. Advances in Therapy 34:7, pages 1622-1635.
Crossref
Crossref
James D. Chalmers, Abigail Tebboth, Alicia Gayle, Andrew Ternouth & Nick Ramscar. (2017) Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. npj Primary Care Respiratory Medicine 27:1.
Crossref
Crossref
S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, A. A. Vizel', S. K. Zyryanov, G. L. Ignatova, N. P. Knyazheskaya, I. V. Leshchenko, S. I. Ovcharenko, A. I. Sinopal'nikov, I. E. Stepanyan & V. I. Trofimov. (2017) New opportunities for prevention of exacerbations of chronic obstructive pulmonary disease. Russian Respiratory Society Expert Opinion. PULMONOLOGIYA 27:1, pages 108-113.
Crossref
Crossref
Nobuyuki Horita, Atsushi Goto, Yuji Shibata, Erika Ota, Kentaro Nakashima, Kenjiro Nagai & Takeshi Kaneko. (2017) Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2018:2.
Crossref
Crossref
Gary T. Ferguson, Jill Karpel, Nathan Bennett, Emmanuelle Clerisme-Beaty, Lars Grönke, Florian Voß & Roland Buhl. (2017) Effect of tiotropium and olodaterol on symptoms and
patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. npj Primary Care Respiratory Medicine 27:1.
Crossref
Crossref
Dave Singh, Marc Miravitlles & Claus Vogelmeier. (2016) Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. Advances in Therapy 34:2, pages 281-299.
Crossref
Crossref
Dave Singh, Mina Gaga, Olaf Schmidt, Leif Bjermer, Lars Grönke, Florian Voß & Gary T. Ferguson. (2016) Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respiratory Research 17:1.
Crossref
Crossref
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini & N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, pages 911-936.
Crossref
Crossref
Edward Kerwin. (2016) A new alphabet for COPD care. European Respiratory Journal 48:4, pages 972-975.
Crossref
Crossref
Kai M. Beeh. (2016) The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases 79:4, pages 241.
Crossref
Crossref